How should bupropion (Wellbutrin) be used and dosed in patients with hepatic impairment?

Bupropion (Wellbutrin) Dosing in Hepatic Impairment

In patients with moderate to severe hepatic impairment (Child-Pugh score 7-15), the maximum dose of bupropion XL is 150 mg every other day; in mild hepatic impairment (Child-Pugh score 5-6), reduce the dose and/or frequency of dosing. 1

Dosing Recommendations by Severity

Moderate to Severe Hepatic Impairment (Child-Pugh B or C)

• Maximum dose: 150 mg every other day 1
• This represents the most restrictive dosing due to significantly increased drug exposure in these patients 1
• Bupropion is extensively metabolized in the liver to active metabolites, which accumulate when hepatic function is compromised 1

Mild Hepatic Impairment (Child-Pugh A)

• Consider reducing the dose and/or frequency of dosing 1
• While specific dosing is not mandated, caution is warranted given the hepatic metabolism pathway 1
• Monitor closely for adverse reactions that could indicate high bupropion or metabolite exposures 1

Combination Products (Naltrexone-Bupropion ER)

• In moderate to severe hepatic impairment: maximum dose is 1 tablet daily (containing 8 mg naltrexone/90 mg bupropion) 2
• This is substantially lower than the standard maintenance dose of 2 tablets twice daily 2

Pharmacokinetic Rationale

The restrictive dosing in hepatic impairment is based on several key pharmacokinetic considerations:

• Bupropion undergoes extensive hepatic metabolism via CYP2B6 to form hydroxybupropion, the primary active metabolite 3
• Two additional active metabolites (threohydrobupropion and erythrohydrobupropion) are formed via non-microsomal pathways 3
• At steady state, hydroxybupropion concentrations are 4-7 fold higher at Cmax and approximately 10-fold greater in AUC compared to the parent drug 3
• In patients with alcoholic liver disease, the elimination half-life of the morpholinol metabolite was significantly prolonged (32.2 vs 21.1 hours), and mean AUC values for bupropion and metabolites were increased 4

Critical Monitoring Parameters

Monitor closely for:

• Signs of excessive drug accumulation (tremor, agitation, seizure risk) 1
• Seizure threshold is lowered by bupropion, making dose reduction particularly important in hepatic impairment 2
• Hepatotoxicity, though rare, has been reported with bupropion use 5, 6

Important Clinical Caveats

Seizure risk considerations:

• Bupropion lowers the seizure threshold in a dose-dependent manner 2
• The reduced dosing in hepatic impairment helps mitigate this risk, but patients should still be counseled 1
• Avoid in patients with seizure disorders or conditions that increase seizure risk 2

Hepatotoxicity potential:

• While bupropion is generally considered safe, acute hepatitis has been reported, typically within 1-6 weeks of initiation 5, 6
• The mechanism appears to be immune-mediated with hypersensitivity features 6
• Discontinuation leads to rapid resolution of liver enzyme abnormalities 5, 6

Assessment of hepatic function:

• The Child-Pugh score remains the standard for categorizing hepatic impairment severity for dosing purposes 1
• This score incorporates bilirubin, albumin, INR, ascites, and encephalopathy 7

Practical Application

For a patient with known cirrhosis:

1. Calculate Child-Pugh score to determine severity
2. If score is 7-15 (moderate to severe): prescribe 150 mg every other day maximum 1
3. If score is 5-6 (mild): reduce from standard dosing, consider 150 mg daily or every other day 1
4. Monitor for signs of drug accumulation and seizure precursors 1
5. Reassess hepatic function periodically as clinical status changes 8

The FDA labeling provides the most authoritative guidance, and these dose reductions are mandatory rather than optional in moderate to severe hepatic impairment to prevent serious adverse outcomes including seizures from drug accumulation 1.